LLibre JM, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. AIDS 2018.,Aboud M, et al. Durable Suppression 2 years after switch to DTG+RPV 2 Drug Regimen: SWORD 1&2 Studies. AIDS 2018.
Nirsevimab voorkomt RSV bij gezonde laat-premature en voldragen zuigelingen
mrt 2022 | Virale infecties